Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Calidi Biotherapeutics Inc

CLDI ✓ COMPLIANT ☆ Track — members

NYSE American · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$1.59

▲ +3.25%

Market Cap $4.11M · Vol 6.26K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$4.11M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

43.00

Momentum

Beta

1.34

vs Market

52W High

$85.60

98.14% below

52W Low

$1.48

7.09% above

Volume

6.26K

Avg 4.84K

P/B

2.25

Price-to-book

ROE

N/A

Return on equity

Free Float

99.08%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Calidi Biotherapeutics Inc (CLDI) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CLDI pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.85%

-18.55%

-47.67%

-87.30%

YTD

-91.51%

-98.03%

-99.99%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-20,063,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-174.04% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	2.25
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	2.58M

Technical Indicators

50-Day SMA	$2.13
200-Day SMA	$10.10
RSI (14)	43.00
Beta	1.34
52-Week High	$85.60
52-Week Low	$1.48

Volume Today	6.26K
Avg Daily Volume (30D)	4.84K
Relative Volume	1.29x
Volatility (10D)	92.25
Volatility (30D)	99.53
Free Float	99.08%

Analyst Consensus

N/A

Current Price $1.59

Mean Target N/A

52W Low$1.48 52W High$85.60

Current

Target

$1.48 $85.60

Current Analyst target

· 0 analysts

Identifiers

ExchangeNYSE American

FIGIBBG012QFCL93

ISINUS3207034089

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. It is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.